DUBLIN, Jan. 16, 2018 /PRNewswire/ --
The "Gene Therapy for Ovarian Cancer - A Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
The report covers the present scenario and the growth prospects of the gene therapy for ovarian cancer for 2018-2022. To calculate the market size, the report considers the revenue generated from the gene therapy.
The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy, which replaces faulty genes with normal ones in the body, is particularly promising and currently gaining attention. It has potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
The latest trend gaining momentum in the market is the adoption of replacement gene therapy. Ovarian cancer has the lowest survival rate among all the other types of gynecological cancers. Epithelial ovarian cancer (EOC) is the most common ovarian cancer witnessed among patients.
Players in the ovarian cancer immunotherapies market have come up with few chemotherapy products that are commercially successful. However, chemotherapy can cause blood-related complications by damaging the blood-producing cells of the bone marrow. This in turn is fueling the popularity of gene therapy which is expected to be one of the biggest paradigm shifts in pharmacology.
- Takara Bio
- Lokon Pharma
- SiBiono GeneTech
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of Report
Part 03: Research Methodology
Part 04: Gene Therapy For Ovarian Cancer: An Insight
Part 05: Major Regulatory Authorities
Part 06: Pipeline Landscape
Part 07: Comparative Analysis
Part 08: Indication Analysis
Part 09: Therapeutic Assessment (Roa Based)
Part 10: Therapeutic Assessment (By Target)
Part 11: Key Companies
For more information about this report visit https://www.researchandmarkets.com/research/23rctx/global_gene?w=5
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets